It is well recognized that Pasteurella multocida infection in rabbits is common and widespread (11) . Pasteurellosis can cause high morbidity and mortality but is most often characterized by subclinical infections of the respiratory, genital, and sensory systems. The effect of this disease on research rabbits is so profound that study of the pathogenesis, serotypes, and development of effective control and preventive methods is of the utmost importance.
In our efforts to develop live vaccines and test their efficacies in preventing rabbit pasteurellosis, it is necessary to obtain epizootiological data, such as serological identification of P. multocida isolates from clinically healthy and diseased rabbits and correlation of serotypes of P. multocida isolates to health states and disease patterns. These data are especially useful in selecting isolates for potential vaccine candidates. Studies in several species suggest that protective immunity elicited by P. multocida vaccines is probably associated with capsular (1, 10, 15) or somatic (12, 14) antigen or both, although there is not agreement as to whether one or both of the antigens are most important in stimulating immunity, which may vary with animal species (12, 14) . Serotyping studies of rabbit isolates are limited (2, 3, 18) , and the information is incomplete in that only one of these studies identifies both capsular and somatic antigens (9) . Furthermore, the study (9) did not indicate whether the isolates were recovered from clinically healthy or diseased rabbits. We feel it is important to type rabbit P. multocida for both capsular and somatic antigens and to correlate serotypes with health states in order to provide more precise information for selecting vaccine candidates. A rational approach for selecting potential candidates is to identify the most commonly distributed, antigenically characterized isolates associated with rabbit pasteurellosis. The purposes of this study were to determine the prevalence of capsular and somatic types of P. multocida isolates recovered from rabbits in Texas and to correlate the serotypes with health status and specific disease patterns. 111; 18%) . Nine of the 111 isolates (8%) reacted with 2 or 4 of the 16 typing sera. When isolates were identified by both capsular and somatic antigens, the major serotypes were serotypes 12:A (32%), 3:A (9%), nontypable:A (37%), and nontypable:D (6%). P. multocida isolates which did not react with the 16 somatic typing sera were designated as nontypable serotypes; however, these isolates may have a somatic antigen comparable to the 16 established serotypes and possibly representing several somatic groups.
Correlation of P. multocida serotypes and health status of rabbits. Of the 111 P. multocida isolates, 48 were recovered from clinically healthy rabbits and 63 from diseased rabbits. The distribution of serotypes from healthy and diseased rabbits is shown in Table 1 . The major serotypes from healthy animals were serotypes 12:A (33%), nontypable:A (50%), and nontypable:D (10o). Similarly, the major serotypes from diseased rabbits were serotypes 12:A (32%), 3 :A (16%), and nontypable:A (30%). Statistical analyses of the nontypable and typable serotypes indicated that nontypable serotypes were isolated more frequently (P < 0.01) from healthy animals. Serotype 3:A was isolated only from diseased rabbits. When compared with the other typable serotypes, serotype 12:A was recovered more frequently (P < 0.01) from clinically healthy rabbits than from diseased rabbits and was the predominant isolate recovered from all rabbits. with type 12 predominating (40%). These findings are in agreement with those of a recent somatic typing study of 48 P. multocida isolates from American and Brazilian rabbits (2), in which it was reported that somatic serotypes 12 and 3 were the two major types, with type 12 greatly predominating (75%). On the basis of our findings and the report (9) that 12:A was the major serotype among the 79 P. multocida isolates recovered from rabbits with unknown health status, we feel that P. multocida serotype 12:A is probably the major serotype associated with healthy and diseased rabbits in the United States. However, a large-scale study of rabbit populations from various geographic locations is required to make a definitive conclusion. When we correlated serotypes with health and disease states of rabbits, we noted that P. multocida serotype 3:A was isolated only from diseased rabbits, whereas P. multocida serotype 12:A was isolated from healthy and diseased rabbits. Rabbits with respiratory lesions from which P. multocida serotype 3:A was cultured also had a higher frequency of conjunctivitis and tympanitis than diseased rabbits from which P. It was surprising that 43% of the 111 isolates were somatically untypable with the 16 known somatic antisera. Although the nontypable serotypes were isolated much more frequently from healthy rabbits, nontypable isolates were also recovered from diseased rabbits. A recent study (19) in Israel reported that a significant number (48 of 51; 94%) of P. multocida isolates from rabbits were somatically unidentifiable as one of the 16 known somatic antigens. Further studies are needed to determine the somatic antigenic components of the nontypable P. multocida isolates and their significance in the pathogenesis of rabbit pasteurellosis.
Recent studies in our laboratory and another laboratory (8, 16) showed that live mutant vaccines produced from serotypes 12:A and 3:A P. multocida isolates significantly reduced or prevented disease in rabbits challenged with homologous virulent P. multocida. The observation in this study that serotypes 12:A and 3:A combined accounted for only about 50% of the P. multocida isolates has highlighted the consideration of using multivalent vaccines to control rabbit pasteurellosis on a broader basis. Also, the efficacy of cross-protection of monovalent vaccines in controlling rabbit pasteurellosis must also be evaluated to determine the need for mono-or multivalent vaccines.
